<DOC>
	<DOCNO>NCT00598507</DOCNO>
	<brief_summary>The purpose study find effective investigational drug name ZK-Epo melanoma . Although ZK-Epo study treatment cancer , approve use treat melanoma . This research do currently limited number treatment option patient melanoma spread distant organ . We expect patient study least 2 cycle . One cycle last 21 day . If tumor grow 2 cycle major side-effects , may receive 6 cycle ZK-Epo . If receive 6 cycle ZK-Epo doctor determine tumor continue shrink , continue treatment ZK-Epo . The number treatment patient receive 6 cycle depend upon doctor feel maximum tumor response ( tumor shrinkage ) . Two treatment give beyond doctor considers point maximum shrinkage . We estimate spend anywhere 1 1/2 month 5 month take part study .</brief_summary>
	<brief_title>Phase II Trial Of ZK-EPO ( ZK 219477 ) ( Sagopilone ) In Metastatic Melanoma</brief_title>
	<detailed_description>Each Cycle 21 day period . On first day cycle patient receive study drug , ZK-Epo , IV infusion 3 hour period . Patients receive study drug every 21 day period . At start cycle patient follow test : - Patients ask question medical history health undergo complete physical exam . - Blood test do check blood cell count organ function ( 1 tablespoon blood take ) . - Performance status test ( determine patient 's ability perform everyday function ) . - A nurse doctor ask patient feel side effect patient may . - Pre Study Visit : Blood test call lactate dehydrogenase ( LDH ) check organ function . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) see patient 's blood clot normally . Electrocardiogram ( EKG ) ( measure electrical function patient 's heart ) . Pregnancy Test ( IF APPLICABLE woman child bear age ) . Optional Tumor Biopsy ( If indicate patient 's physician ) . - Cycle 1 , Day 1 : Pharmacokinetics : special blood test measure drug level , LDH - Cycle 1 , Day 2 &amp; 8 : Pharmacokinetics - Cycle 1 , Day 15 : EKG - Cycle 2 , DAY 1 : LDH - Cycle 3 , DAY 1 : LDH , PT &amp; activate partial thromboplastin time ( aPTT ) - Cycle 4 , 5 , &amp; 6 , subsequent cycle , Day 1 : LDH During first cycle patient also need come study visit day 8 15 . During two visit , blood test do check blood cell count organ function . Patients also ask feeling side effect may . Computed tomography ( CT ) scan magnetic resonance imaging ( MRI ) do every 2 cycle patient completes study . These do help doctor re-evaluate patient 's disease . Patients may additional blood test do among first 10 patient take part study . In case 9 sample blood ( teaspoonful ) drawn specifically time interval ( 30 minute start 30 minute , 2 hour 55 minute , 3 hour 10 minute , 3 hour 30 minute , 5 hour , 8 hour , 27 hour ( +/- 1 hour ) 168 hour ( +/- 4 hour ) start ZK-Epo infusion ) good understand level drug body metabolism people .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologically cytologically confirm Malignant Melanoma . Unresectable Stage III Stage IV disease . At least 1 measurable lesion . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Adequate function major organ system measure follow criterion : Bone Marrow : Hemoglobin ≥ 10 g/dL White blood count ( WBC ) ≥ 3,000/mm^3 Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : Bilirubin within 1.5 time normal limit aspartate transaminase ( AST ) /Alanine aminotransferase ( ALT ) ≤ 5 time upper limit normal ( ULN ) Renal : Creatinine ≤ 2 mg/dL Cardiovascular : No New York Heart Association ( NYHA ) class III IV Congestive heart failure No unstable angina pectoris No arrhythmia need continuous treatment Nervous system : No Grade ≥ 2 peripheral neuropathy More 2 previous chemotherapy regimen . Any prior treatment Epothilones , Epothilone analogues , taxanes , vinca alkaloid . Any progressive central nervous system ( CNS ) metastatic disease . Patients CNS metastasis may allow stable 8 week patient neurologically intact steroid . The stability must document MRI/CT period 8 week great . Any radiotherapy , chemotherapy , immunotherapy within 3 week prior first dose ZKEpo . If patient previously temozolomide extend dose schedule , must 1 week prior first dose ZKEpo .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ZK-EPO</keyword>
	<keyword>ZK219477</keyword>
	<keyword>EpothiloneZK</keyword>
</DOC>